OpGen Inc (OPGN)-医療機器分野:企業M&A・提携分析

◆英語タイトル:OpGen Inc (OPGN) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8010943
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月21日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, swift detection and analysis of antibiotic resistance, and detection of pathogens in blood cultures. It is also developing Acuitas Lighthouse, an exhaustive database of various types of pathogens for providing rapid diagnostics, and healthcare management information. OpGen offers its surveillance products and customized screening services to healthcare providers to protect the hospital biome and optimize patient care. The company sells its products in the US and abroad. OpGen is headquartered in Gaithersburg, Maryland, the US.

OpGen Inc (OPGN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OpGen Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
OpGen Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
OpGen Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
OpGen Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
OpGen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
OpGen Inc, Medical Equipment, Deal Details 12
Venture Financing 12
AdvanDx Raises USD2.5 Million in Venture Financing 12
OpGen Raises USD1.2 Million in Venture Financing 13
Opgen Raises USD1 Million in Venture Financing 14
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 15
OpGen Raises US$2 Million In Venture Financing 16
AdvanDx Raises US$2 Million In Venture Financing 17
OpGen Raises Additional US$2.6 Million In Series C Financing 18
OpGen Secures An Additional US$3 Million In Series B Round Of Financing 20
Partnerships 22
OpGen Enters into Research Agreement with Merck 22
OpGen Enters into Co-Development Agreement with Fluidigm 23
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 24
OpGen Enters Into Co-Development Agreement With In-Q-Tel 25
Equity Offering 26
OpGen Plans to Raise Funds through Public Offering of Units 26
Opgen Raises USD10 Million in Public Offering of Units 27
OpGen to Raise upto USD11.5 Million in Public Offering of Shares 29
OpGen Raises USD10.4 Million in Private Placement of Shares and Warrants 30
OpGen Raises USD17 Million in IPO 32
Debt Offering 34
OpGen Raises USD0.5 Million in Debt Financing 34
OpGen Raises USD1.5 Million in Private Placement of 8% Notes 35
Acquisition 36
OpGen Acquires AdvanDx 36
OpGen Inc – Key Competitors 37
OpGen Inc – Key Employees 38
OpGen Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Nov 07, 2017: OpGen Reports 2017 Third Quarter Financial Results and Provides Business Update 40
Aug 08, 2017: OpGen Reports 2017 Second Quarter Financial Results and Provides Business Update 42
Apr 26, 2017: OpGen Announces 2017 First Quarter Financial Results 44
Mar 23, 2017: OpGen Announces 2016 Fourth Quarter and Year End Financial Results 45
Jan 26, 2017: OpGen Reports Preliminary Fourth Quarter and Full Year 2016 Financial Results 47
Oct 24, 2016: OpGen Reports 2016 Third Quarter Financial Results and Provides Business Update 49
Aug 09, 2016: OpGen Reports 2016 Second Quarter Financial Results and Provides Business Update 50
May 12, 2016: OpGen Reports 2016 First Quarter Financial Results and Business Update 51
Mar 30, 2016: OpGen Announces 2015 Fourth Quarter and Full Year Financial Results 52
Corporate Communications 53
Apr 27, 2017: OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors 53
May 02, 2016: OpGen Appoints Harry J. D’Andrea to Board of Directors 54
Mar 21, 2016: OpGen Announces New Members to its Clinical Advisory Board 55
Government and Public Interest 56
May 04, 2016: OpGen and District of Columbia Hospital Association Complete First Citywide Quantification of Multidrug-Resistant Organism (MDRO) Prevalence in Washington, D.C.-based Healthcare Facilities 56
Product News 57
Apr 12, 2017: OpGen to Present Antibiotic Resistance Prediction Data at 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 57
Feb 14, 2017: OpGen Presents Rapid Acuitas Genetic Test Data at Advances in Genome Biology and Technology Meeting 59
Oct 26, 2016: Opgen’s Infectious Disease Portfolio Highlighted At IDWeek 2016 60
Other Significant Developments 61
Jun 15, 2017: OpGen’s Acuitas Detection Technology Utilized in Publication Revealing Prevalence of CRE in Washington D.C. Healthcare Facilities 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
OpGen Inc, Medical Equipment, Key Facts, 2016 2
OpGen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
OpGen Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
OpGen Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
OpGen Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
OpGen Inc, Deals By Market, 2011 to YTD 2017 9
OpGen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
AdvanDx Raises USD2.5 Million in Venture Financing 12
OpGen Raises USD1.2 Million in Venture Financing 13
Opgen Raises USD1 Million in Venture Financing 14
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 15
OpGen Raises US$2 Million In Venture Financing 16
AdvanDx Raises US$2 Million In Venture Financing 17
OpGen Raises Additional US$2.6 Million In Series C Financing 18
OpGen Secures An Additional US$3 Million In Series B Round Of Financing 20
OpGen Enters into Research Agreement with Merck 22
OpGen Enters into Co-Development Agreement with Fluidigm 23
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 24
OpGen Enters Into Co-Development Agreement With In-Q-Tel 25
OpGen Plans to Raise Funds through Public Offering of Units 26
Opgen Raises USD10 Million in Public Offering of Units 27
OpGen to Raise upto USD11.5 Million in Public Offering of Shares 29
OpGen Raises USD10.4 Million in Private Placement of Shares and Warrants 30
OpGen Raises USD17 Million in IPO 32
OpGen Raises USD0.5 Million in Debt Financing 34
OpGen Raises USD1.5 Million in Private Placement of 8% Notes 35
OpGen Acquires AdvanDx 36
OpGen Inc, Key Competitors 37
OpGen Inc, Key Employees 38
OpGen Inc, Subsidiaries 39

★海外企業調査レポート[OpGen Inc (OPGN)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HP Inc.:企業の戦略・SWOT・財務情報
    HP Inc. - Strategy, SWOT and Corporate Finance Report Summary HP Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • B. Braun Melsungen AG-製薬・医療分野:企業M&A・提携分析
    Summary B. Braun Melsungen AG (B. Braun) is a global health care company. It offers products and solutions for therapy fields and applications including acute dialysis, infusion therapy, apheresis, interventional vascular, diagnostics and treatment, cardio-thoracic surgery, laparoscopy, degenerative …
  • Biosceptre International Ltd:企業の製品パイプライン分析2018
    Summary Biosceptre International Ltd (Biosceptre) is a biotechnology company that develops antibody technologies for applications in the diagnosis and treatment of cancer. The company develops imaging technologies to detect and monitor cancer. Its diagnostic products are used for the detection of va …
  • Fujifilm Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Fujifilm Corp (Fujifilm), a subsidiary of Fujifilm Holdings Corporation, is a provider of imaging and information solutions. The company’s product portfolio encompasses color films, optical devices, digital cameras, photofinishing equipment and color paper, chemicals and services for photofi …
  • Reach PLC:企業の戦略・SWOT・財務分析
    Reach PLC - Strategy, SWOT and Corporate Finance Report Summary Reach PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG; BAY 1905254, COM902 and TIGIT; and autoimmune diseases pipeline includes CGEN …
  • TAS S.p.A. (TAS):企業の財務・戦略的SWOT分析
    TAS S.p.A. (TAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Nano Intelligent Biomedical Engineering Corp (138610):医療機器:M&Aディール及び事業提携情報
    Summary Nano Intelligent Biomedical Engineering Corp (NIBEC) is a venture firm. The firm manufacture of tissue regeneration devices. It aims to research ideas for tissue regeneration treatments and to develop and manufacture devices for practical use. NIBEC offers bio fusion peptide-based products, …
  • Wyndham Destinations, Inc.:企業の戦略・SWOT・財務情報
    Wyndham Destinations, Inc. - Strategy, SWOT and Corporate Finance Report Summary Wyndham Destinations, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • AeroVironment Inc:企業の戦略・SWOT・財務情報
    AeroVironment Inc - Strategy, SWOT and Corporate Finance Report Summary AeroVironment Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • XBiotech Inc (XBIT):企業の財務・戦略的SWOT分析
    Summary XBiotech Inc (XBiotech) is a biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company offers monoclonal antibodies treatment for various diseases. It’s lead product Xilonix, a therapeutic antibody being developed fo …
  • Siemens Ltd (SIEMENS):企業の財務・戦略的SWOT分析
    Siemens Ltd (SIEMENS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Selventa Inc-製薬・医療分野:企業M&A・提携分析
    Summary Selventa Inc (Selventa), formerly Genstruct Inc is a healthcare technology services provider that operates life science consulting projects. The company offers system diagnostic development services that identifies molecular mechanisms, networks and biomarkers to develop therapeutics, molecu …
  • Windtree Therapeutics Inc (WINT):製薬・医療:M&Aディール及び事業提携情報
    Summary Windtree Therapeutics Inc (Windtree Therapeutics), formerly Discovery Laboratories, Inc. is a specialty biotechnology company. It focuses on the development of novel KL4 surfactant therapies for patients with respiratory diseases and other potential applications. The company’s lead developme …
  • Suburban Propane Partners LP (SPH):企業の財務・戦略的SWOT分析
    Summary Suburban Propane Partners LP (Suburban Propane) distributes and markets energy-related products. The company supplies propane, fuel oil and refined fuels, and markets natural gas and electricity in deregulated markets. Suburban Propane also provides installation and service of various types …
  • Protalex Inc (PRTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Protalex Inc (Protalex) is a biopharmaceutical company that develops drugs for the treatment of autoimmune and inflammatory diseases. The company offers treatment for a range of autoimmune diseases such as rheumatoid arthritis and immune thrombocytopenia. Its lead product candidate includes …
  • Corning Incorporated (GLW)-医療機器分野:企業M&A・提携分析
    Summary Corning Incorporated (Corning) manufactures and sells ceramics, specialty glasses and related materials. The company’s product portfolio includes glass substrates, which find application in LCD televisions, computer monitors and laptops; optical fibers, cable, hardware and equipment for tele …
  • AGL Energy Ltd (AGL):企業の財務・戦略的SWOT分析
    AGL Energy Ltd (AGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • American Woodmark Corp (AMWD):企業の財務・戦略的SWOT分析
    American Woodmark Corp (AMWD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Alliance Data Systems Corporation:企業の戦略・SWOT・財務分析
    Alliance Data Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary Alliance Data Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆